A prospective multi-center observational study of surgical versus non-surgical management for pituitary apoplexy.

Pituitary apoplexy registry transsphenoidal surgery treatment outcomes

Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
12 Sep 2023
Historique:
received: 01 06 2023
revised: 14 08 2023
accepted: 08 09 2023
medline: 12 9 2023
pubmed: 12 9 2023
entrez: 12 9 2023
Statut: aheadofprint

Résumé

Pituitary apoplexy (PA) has been traditionally considered a neurosurgical emergency, yet retrospective single-institution studies suggest similar outcomes among patients managed medically. We established a multicenter international prospective registry to compare presentation and outcomes in PA patients treated with surgery or medical management alone. A centralized database captured demographics, comorbidities, clinical presentation, visual findings, hormonal status, and imaging features at admission. Treatment was determined independently by each site. Key outcomes included visual, oculomotor, and hormonal recovery, complications, and hospital length of stay. Outcomes were also compared based on time from symptom onset to surgery, and from admission or transfer to the treating center. Statistical testing compared treatment groups based on two-sided hypotheses and p < 0.05. 100 consecutive PA patients from 12 hospitals were enrolled, and 97 (67 surgical and 30 medical) were evaluable. Demographics, clinical features, presenting symptoms, hormonal deficits, and imaging findings were similar between groups. Severe temporal visual field deficit was more common in surgical patients. At 3 and 6 months, hormonal, visual, and oculomotor outcomes were similar. Stratifying based on severity of visual fields demonstrated no difference in any outcome at 3 months. Timing of surgery did not impact outcomes. We found that medical and surgical management of PA yield similar 3-month outcomes. Although patients undergoing surgery had more severe visual field deficits, we could not clearly demonstrate that surgery led to better outcomes. Even without surgery, apoplectic tumor volumes regress substantially within 2-3 months, indicating that surgery is not always needed to reduce mass effect.

Identifiants

pubmed: 37698130
pii: 7270439
doi: 10.1210/clinem/dgad541
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Adam N Mamelak (AN)

Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California USA.

Andrew S Little (AS)

Department of Neurosurgery, Barrow Neurological Institute, St Joseph's Medical Center, Phoenix, Arizona USA.

Paul A Gardner (PA)

Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania USA.

João Paulo Almeida (JP)

Department of Neurosurgery, Mayo Clinic, Jacksonville, Florida USA.

Pablo Recinos (P)

Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland, Ohio USA.

Pranay Soni (P)

Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland, Ohio USA.

Varun R Kshettry (VR)

Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland, Ohio USA.

John A Jane (JA)

Departments of Neurosurgery, Virginia Tech Medical Center, Roanoke, Virginia USA.

Garni Barkhoudarian (G)

Pacific Neuroscience Institute, St John's Medical Center, Santa Monica, California USA.

Daniel F Kelly (DF)

Pacific Neuroscience Institute, St John's Medical Center, Santa Monica, California USA.

Robert Dodd (R)

Department of Neurosurgery, Stanford University Medical Center, Stanford, California USA.

Debraj Mukherjee (D)

Department of Neurosurgery, Johns Hopkins University, Baltimore, Maryland USA.

Zachary C Gersey (ZC)

Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania USA.

Noriaki Fukuhara (N)

Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo, Japan.

Hiroshi Nishioka (H)

Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo, Japan.

Eui-Hyun Kim (EH)

Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Korea.

Claude-Fabien Litré (CF)

Department of Neurosurgery, CHU de Reims, Reims, France.

Elliott Sina (E)

Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California USA.

Mia W Mazer (MW)

Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California USA.

Yujie Cui (Y)

Biostatistic Core, Cedars Sinai Medical Center, Los Angeles.

Vivien Bonert (V)

Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Classifications MeSH